Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells

NMR in Biomedicine

Volumn 25, Issue 2, 2012, Pages 379-388

  Su, Judy S ^a   Woods, Sarah M ^a   Ronen, Sabrina M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Choline metabolism; Magnetic resonance spectroscopy (MRS); Perifosine; PI3K Akt signaling

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; CHOLINE KINASE; CLINICAL TRIAL; EXTRACELLULAR; HUMAN CANCER; HYPERPOLARIZED; HYPOXIA-INDUCIBLE FACTORS; INTRACELLULAR LACTATE; LACTATE DEHYDROGENASE; MCF-7 BREAST CANCER CELLS; METABOLIC CHANGES; PERIFOSINE; PHOSPHOCHOLINE;

CELL CULTURE; CELLS; DISEASES; ENZYME ACTIVITY; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; PHOSPHORYLATION; TRANSCRIPTION FACTORS;

DROPS;

CHOLINE KINASE; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTIC ACID; PERIFOSINE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL LYSATE; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METABOLIC CAPACITY; OUTCOME ASSESSMENT; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHOLINE; CHOLINE KINASE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; FEMALE; HUMANS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORYLCHOLINE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84855983451     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1764     Document Type: Article

References (51)

1. Fresna-Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30: 193-204.
2. Pawson T, Nash P. Protein-protein interaction define specificity in signal transduction. Genes Dev. 2000; 14: 1027-1047.
3. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7: 606-619.
4. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001; 3: 304-312.
5. Vivanco I, Sawyers CL. The Phosphatidylinositol 3-Kinase-Akt Pathway in Human Cancer. Nat Rev Cancer 2002; 2: 489-501.
6. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4: 988-1004.
7. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28: 1075-1083.
8. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
9. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001; 84: 691-696.
10. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther. 2006; 5: 187-196.
11. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010; 12: 559-569.
12. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010; 70: 1296-1305.
13. Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, Wang C, Zhang X, Vigneron DB, Ronen SM. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res. 2010; 70: 7400-7410.
14. Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, de Molina AR, Lacal JC, Workman P, Leach MO. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase a leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res. 2010; 70: 5507-5517.
15. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst. 2003; 95: 1624-1633.
16. Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen SM. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging 2008; 7: 92-100.
17. Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 2008; 10: 303-313.
18. Brandes AH, Ward CS, Ronen SM. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res. 2010; 12: R84.
19. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep. 2010; 11: 102-110.
20. van Blitterswijk WJ, Verheij M. Anticancer Alkylphosphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects. Curr Pharm Des. 2008; 14: 2061-2074.
21. Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser MSR, Knebel NG, Schellens JHM, Beijnen JH, ten Bokkel Huinink WW. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer. 2002; 38: 1615-1621.
22. Elrod HA, Lin Y-D, Yue P, Wang X, Lonial S, Khuri FR, Sun S-Y. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther. 2007; 6: 2029-2038.
23. van der Luit AH, Vink SR, Klarenbeek JB, Perrissound D, Solary E, Verheij M, van Blitterswijk WJ. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther. 2007; 6: 2337-2345.
24. Boggs KP, Rock CO, Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem. 1995; 270: 7757-7764.
25. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003; 2: 1093-1103.
26. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs. 2003; 14: 167-173.
27. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007; 13: 7421-7431.
28. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ, Jr., Harris CC. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA. 1999; 96: 3706-3711.
29. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther. 2008; 7: 2556-2565.
30. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002; 16: 1472-1487.
31. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous Extraction of Cellular Lipids and Water-Soluble Metabolites: Evaluation by NMR Spectroscopy. MRM 1996; 35: 194-200.
32. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression. Cancer Res. 2005; 65: 9369-9376.
33. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F. Activation of Phosphotidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells. Cancer Res. 2010; 70: 2126-2135.
34. van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem. 2002; 277: 39541-39547.
35. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
36. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
37. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262-269.
38. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443.
39. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777.
40. WAF1expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002; 62: 1401-1409.
41. Floryk D, Thompson T. Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett. 2008; 266(2): 216-226.
42. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, Morishita Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999; 90: 419-424.
43. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004; 64: 6732-6739.
44. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002; 21: 4317-4322.
45. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Rosell R, Gonzalez-Baron M, Lacal JC. Expression of choline kinase alpha to predict outcome in patients eith early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007; 8: 889-897.
46. Glunde K, Shah T, Winnard PT, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1α signaling in a human prostate cancer model. Cancer Res 2008; 68: 172-180.
47. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005; 24: 3574-3582.
48. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 10: 763-777.
49. Jackowski S, Fagone P. CTP: Phosphocholine cytidylyltransferase: paving the way from gene to membrane. J Biol Chem. 2005; 280: 853-856.
50. Kent C. CTP:phosphocholine cytidylyltransferase. Biochim Biophys Acta. 1997; 1348: 79-90.
51. Sugimoto H, Banchio C, Vance DE. Transcriptional regulation of phosphatidylcholine biosynthesis. Prog Lipid Res. 2008; 47: 204-220.